Tahir Ph.D. Mahmood - 27 Dec 2023 Form 4 Insider Report for Applied Molecular Transport Inc.

Role
Director
Signature
/s/ Brandon Hants Attorney-in-Fact for Tahir Mahmood
Issuer symbol
N/A
Transactions as of
27 Dec 2023
Net transactions value
$0
Form type
4
Filing time
28 Dec 2023, 17:32:58 UTC
Previous filing
27 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMTI Common Stock Disposed to Issuer -484,738 -100% 0 27 Dec 2023 Direct F1, F2
transaction AMTI Common Stock Disposed to Issuer -3,208,307 -100% 0 27 Dec 2023 By Living Trust F3, F4
transaction AMTI Common Stock Disposed to Issuer -391,693 -100% 0 27 Dec 2023 By Irrevocable Trust F5, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMTI Stock Option (Right to Buy) Disposed to Issuer $0 -164,000 -100% $0.000000* 0 27 Dec 2023 Common Stock 164,000 $56.61 Direct F7
transaction AMTI Stock Option (Right to Buy) Disposed to Issuer $0 -350,000 -100% $0.000000* 0 27 Dec 2023 Common Stock 350,000 $8.29 Direct F7
transaction AMTI Stock Option (Right to Buy) Disposed to Issuer $0 -20,000 -100% $0.000000* 0 27 Dec 2023 Common Stock 20,000 $0.3400 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Tahir Ph.D. Mahmood is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Pursuant to the Agreement and Plan of Merger dated as of September 21, 2023 (the "Merger Agreement"), by and among Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc. and the Issuer, each share of Issuer's Common Stock was converted into 0.1331 of a share of Cyclo Common Stock (the "Transaction Consideration").
F2 Upon closing of the Merger, the Reporting Person received Transaction Consideration of 64,519 shares of Cyclo common stock.
F3 Upon closing of the Merger, the Reporting Person received Transaction Consideration of 427,026 shares of Cyclo common stock.
F4 These shares are held directly by the Mahmood-Shamsi Living Trust Agreement for which the Reporting Person and spouse serve as co-trustees and over which shares the Reporting Person and his spouse hold voting and dispositive power.
F5 Upon closing of the Merger, the Reporting Person received Transaction Consideration of 52,135 shares of Cyclo common stock.
F6 These shares are held directly by The Mahmood 2017 Irrevocable Trust for which the Reporting Person serves as trustee and over which shares the Reporting Person hold voting and dispositive power.
F7 Pursuant to the Merger Agreement, at the effective time of the merger, each outstanding option with an exercise price of $0.40 or more was cancelled effective as of the closing.
F8 Pursuant to the terms of the Merger Agreement, this option was exchanged for an option covering 2,662 shares of Cyclo Common Stock.